

Global Genetic COPD Market Insights, Forecast to 2029

https://marketpublishers.com/r/GE895B4626FBEN.html

Date: December 2023

Pages: 127

Price: US\$ 4,900.00 (Single User License)

ID: GE895B4626FBEN

Abstracts

This report presents an overview of global market for Genetic COPD market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Genetic COPD, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Genetic COPD, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Genetic COPD revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Genetic COPD market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Genetic COPD revenue, projected growth trends, production technology, application and enduser industry.

Descriptive company profiles of the major global players, including Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline and CSL Behring, etc.



By Company	
Pfizer	
Baxter	
AstraZeneca	
Grifols	
Teva Pharmaceutical Industries	
Boehringer Ingelheim	
Kamada Ltd	
GlaxoSmithKline	
CSL Behring	
Takeda	
LFB Biomedicaments	
Abeona Therapeutics	
Biogen	
Vertex Pharmaceuticals	
Baxalta	
Arrowhead Research Corporation	
ProBioGen	
Chiesi Pharmaceuticals	



Kedrion Group				
ProMetic Life Sciences				
Segment by Type				
Augmentation Therapy				
Cystic Fibrosis(CF)				
Non-CF Bronchiectasis(NCFB)				
Other				
Segment by Application				
Hospitals				
Specialty Clinics				
Pharmacies				
Others				
By Region				
North America				
United States				
Canada				
Europe				
0				

Germany



France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America

Turkey



Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Genetic COPD in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Genetic COPD companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.



Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genetic COPD revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions



Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Genetic COPD Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
 - 1.2.2 Augmentation Therapy
 - 1.2.3 Cystic Fibrosis(CF)
 - 1.2.4 Non-CF Bronchiectasis(NCFB)
 - 1.2.5 Other
- 1.3 Market by Application
- 1.3.1 Global Genetic COPD Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
 - 1.3.2 Hospitals
 - 1.3.3 Specialty Clinics
 - 1.3.4 Pharmacies
 - 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Genetic COPD Market Perspective (2018-2029)
- 2.2 Global Genetic COPD Growth Trends by Region
 - 2.2.1 Genetic COPD Market Size by Region: 2018 VS 2022 VS 2029
 - 2.2.2 Genetic COPD Historic Market Size by Region (2018-2023)
 - 2.2.3 Genetic COPD Forecasted Market Size by Region (2024-2029)
- 2.3 Genetic COPD Market Dynamics
 - 2.3.1 Genetic COPD Industry Trends
 - 2.3.2 Genetic COPD Market Drivers
 - 2.3.3 Genetic COPD Market Challenges
 - 2.3.4 Genetic COPD Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Revenue Genetic COPD by Players



- 3.1.1 Global Genetic COPD Revenue by Players (2018-2023)
- 3.1.2 Global Genetic COPD Revenue Market Share by Players (2018-2023)
- 3.2 Global Genetic COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Global Key Players of Genetic COPD, Ranking by Revenue, 2021 VS 2022 VS 2023
- 3.4 Global Genetic COPD Market Concentration Ratio
 - 3.4.1 Global Genetic COPD Market Concentration Ratio (CR5 and HHI)
 - 3.4.2 Global Top 10 and Top 5 Companies by Genetic COPD Revenue in 2022
- 3.5 Global Key Players of Genetic COPD Head office and Area Served
- 3.6 Global Key Players of Genetic COPD, Product and Application
- 3.7 Global Key Players of Genetic COPD, Date of Enter into This Industry
- 3.8 Mergers & Acquisitions, Expansion Plans

4 GENETIC COPD BREAKDOWN DATA BY TYPE

- 4.1 Global Genetic COPD Historic Market Size by Type (2018-2023)
- 4.2 Global Genetic COPD Forecasted Market Size by Type (2024-2029)

5 GENETIC COPD BREAKDOWN DATA BY APPLICATION

- 5.1 Global Genetic COPD Historic Market Size by Application (2018-2023)
- 5.2 Global Genetic COPD Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Genetic COPD Market Size (2018-2029)
- 6.2 North America Genetic COPD Market Size by Type
 - 6.2.1 North America Genetic COPD Market Size by Type (2018-2023)
 - 6.2.2 North America Genetic COPD Market Size by Type (2024-2029)
 - 6.2.3 North America Genetic COPD Market Share by Type (2018-2029)
- 6.3 North America Genetic COPD Market Size by Application
 - 6.3.1 North America Genetic COPD Market Size by Application (2018-2023)
- 6.3.2 North America Genetic COPD Market Size by Application (2024-2029)
- 6.3.3 North America Genetic COPD Market Share by Application (2018-2029)
- 6.4 North America Genetic COPD Market Size by Country
 - 6.4.1 North America Genetic COPD Market Size by Country: 2018 VS 2022 VS 2029
 - 6.4.2 North America Genetic COPD Market Size by Country (2018-2023)
 - 6.4.3 North America Genetic COPD Market Size by Country (2024-2029)
 - 6.4.4 United States



6.4.5 Canada

7 EUROPE

- 7.1 Europe Genetic COPD Market Size (2018-2029)
- 7.2 Europe Genetic COPD Market Size by Type
- 7.2.1 Europe Genetic COPD Market Size by Type (2018-2023)
- 7.2.2 Europe Genetic COPD Market Size by Type (2024-2029)
- 7.2.3 Europe Genetic COPD Market Share by Type (2018-2029)
- 7.3 Europe Genetic COPD Market Size by Application
 - 7.3.1 Europe Genetic COPD Market Size by Application (2018-2023)
 - 7.3.2 Europe Genetic COPD Market Size by Application (2024-2029)
 - 7.3.3 Europe Genetic COPD Market Share by Application (2018-2029)
- 7.4 Europe Genetic COPD Market Size by Country
- 7.4.1 Europe Genetic COPD Market Size by Country: 2018 VS 2022 VS 2029
- 7.4.2 Europe Genetic COPD Market Size by Country (2018-2023)
- 7.4.3 Europe Genetic COPD Market Size by Country (2024-2029)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries

8 CHINA

- 8.1 China Genetic COPD Market Size (2018-2029)
- 8.2 China Genetic COPD Market Size by Type
 - 8.2.1 China Genetic COPD Market Size by Type (2018-2023)
 - 8.2.2 China Genetic COPD Market Size by Type (2024-2029)
 - 8.2.3 China Genetic COPD Market Share by Type (2018-2029)
- 8.3 China Genetic COPD Market Size by Application
 - 8.3.1 China Genetic COPD Market Size by Application (2018-2023)
 - 8.3.2 China Genetic COPD Market Size by Application (2024-2029)
 - 8.3.3 China Genetic COPD Market Share by Application (2018-2029)

9 ASIA (EXCLUDING CHINA)

9.1 Asia Genetic COPD Market Size (2018-2029)



- 9.2 Asia Genetic COPD Market Size by Type
 - 9.2.1 Asia Genetic COPD Market Size by Type (2018-2023)
 - 9.2.2 Asia Genetic COPD Market Size by Type (2024-2029)
 - 9.2.3 Asia Genetic COPD Market Share by Type (2018-2029)
- 9.3 Asia Genetic COPD Market Size by Application
 - 9.3.1 Asia Genetic COPD Market Size by Application (2018-2023)
 - 9.3.2 Asia Genetic COPD Market Size by Application (2024-2029)
 - 9.3.3 Asia Genetic COPD Market Share by Application (2018-2029)
- 9.4 Asia Genetic COPD Market Size by Region
 - 9.4.1 Asia Genetic COPD Market Size by Region: 2018 VS 2022 VS 2029
 - 9.4.2 Asia Genetic COPD Market Size by Region (2018-2023)
 - 9.4.3 Asia Genetic COPD Market Size by Region (2024-2029)
 - 9.4.4 Japan
 - 9.4.5 South Korea
 - 9.4.6 China Taiwan
 - 9.4.7 Southeast Asia
 - 9.4.8 India
 - 9.4.9 Australia

10 MIDDLE EAST, AFRICA, AND LATIN AMERICA

- 10.1 Middle East, Africa, and Latin America Genetic COPD Market Size (2018-2029)
- 10.2 Middle East, Africa, and Latin America Genetic COPD Market Size by Type
- 10.2.1 Middle East, Africa, and Latin America Genetic COPD Market Size by Type (2018-2023)
- 10.2.2 Middle East, Africa, and Latin America Genetic COPD Market Size by Type (2024-2029)
- 10.2.3 Middle East, Africa, and Latin America Genetic COPD Market Share by Type (2018-2029)
- 10.3 Middle East, Africa, and Latin America Genetic COPD Market Size by Application 10.3.1 Middle East, Africa, and Latin America Genetic COPD Market Size by Application (2018-2023)
- 10.3.2 Middle East, Africa, and Latin America Genetic COPD Market Size by Application (2024-2029)
- 10.3.3 Middle East, Africa, and Latin America Genetic COPD Market Share by Application (2018-2029)
- 10.4 Middle East, Africa, and Latin America Genetic COPD Market Size by Country 10.4.1 Middle East, Africa, and Latin America Genetic COPD Market Size by Country: 2018 VS 2022 VS 2029



- 10.4.2 Middle East, Africa, and Latin America Genetic COPD Market Size by Country (2018-2023)
- 10.4.3 Middle East, Africa, and Latin America Genetic COPD Market Size by Country (2024-2029)
 - 10.4.4 Brazil
 - 10.4.5 Mexico
 - 10.4.6 Turkey
 - 10.4.7 Saudi Arabia
 - 10.4.8 Israel
 - 10.4.9 GCC Countries

11 KEY PLAYERS PROFILES

- 11.1 Pfizer
 - 11.1.1 Pfizer Company Details
 - 11.1.2 Pfizer Business Overview
 - 11.1.3 Pfizer Genetic COPD Introduction
 - 11.1.4 Pfizer Revenue in Genetic COPD Business (2018-2023)
 - 11.1.5 Pfizer Recent Developments
- 11.2 Baxter
 - 11.2.1 Baxter Company Details
 - 11.2.2 Baxter Business Overview
 - 11.2.3 Baxter Genetic COPD Introduction
 - 11.2.4 Baxter Revenue in Genetic COPD Business (2018-2023)
 - 11.2.5 Baxter Recent Developments
- 11.3 AstraZeneca
 - 11.3.1 AstraZeneca Company Details
 - 11.3.2 AstraZeneca Business Overview
 - 11.3.3 AstraZeneca Genetic COPD Introduction
 - 11.3.4 AstraZeneca Revenue in Genetic COPD Business (2018-2023)
 - 11.3.5 AstraZeneca Recent Developments
- 11.4 Grifols
 - 11.4.1 Grifols Company Details
 - 11.4.2 Grifols Business Overview
 - 11.4.3 Grifols Genetic COPD Introduction
 - 11.4.4 Grifols Revenue in Genetic COPD Business (2018-2023)
 - 11.4.5 Grifols Recent Developments
- 11.5 Teva Pharmaceutical Industries
 - 11.5.1 Teva Pharmaceutical Industries Company Details



- 11.5.2 Teva Pharmaceutical Industries Business Overview
- 11.5.3 Teva Pharmaceutical Industries Genetic COPD Introduction
- 11.5.4 Teva Pharmaceutical Industries Revenue in Genetic COPD Business (2018-2023)
 - 11.5.5 Teva Pharmaceutical Industries Recent Developments
- 11.6 Boehringer Ingelheim
 - 11.6.1 Boehringer Ingelheim Company Details
 - 11.6.2 Boehringer Ingelheim Business Overview
 - 11.6.3 Boehringer Ingelheim Genetic COPD Introduction
 - 11.6.4 Boehringer Ingelheim Revenue in Genetic COPD Business (2018-2023)
 - 11.6.5 Boehringer Ingelheim Recent Developments
- 11.7 Kamada Ltd
- 11.7.1 Kamada Ltd Company Details
- 11.7.2 Kamada Ltd Business Overview
- 11.7.3 Kamada Ltd Genetic COPD Introduction
- 11.7.4 Kamada Ltd Revenue in Genetic COPD Business (2018-2023)
- 11.7.5 Kamada Ltd Recent Developments
- 11.8 GlaxoSmithKline
 - 11.8.1 GlaxoSmithKline Company Details
 - 11.8.2 GlaxoSmithKline Business Overview
 - 11.8.3 GlaxoSmithKline Genetic COPD Introduction
 - 11.8.4 GlaxoSmithKline Revenue in Genetic COPD Business (2018-2023)
 - 11.8.5 GlaxoSmithKline Recent Developments
- 11.9 CSL Behring
 - 11.9.1 CSL Behring Company Details
 - 11.9.2 CSL Behring Business Overview
 - 11.9.3 CSL Behring Genetic COPD Introduction
 - 11.9.4 CSL Behring Revenue in Genetic COPD Business (2018-2023)
- 11.9.5 CSL Behring Recent Developments
- 11.10 Takeda
 - 11.10.1 Takeda Company Details
 - 11.10.2 Takeda Business Overview
 - 11.10.3 Takeda Genetic COPD Introduction
 - 11.10.4 Takeda Revenue in Genetic COPD Business (2018-2023)
 - 11.10.5 Takeda Recent Developments
- 11.11 LFB Biomedicaments
 - 11.11.1 LFB Biomedicaments Company Details
 - 11.11.2 LFB Biomedicaments Business Overview
 - 11.11.3 LFB Biomedicaments Genetic COPD Introduction



- 11.11.4 LFB Biomedicaments Revenue in Genetic COPD Business (2018-2023)
- 11.11.5 LFB Biomedicaments Recent Developments
- 11.12 Abeona Therapeutics
 - 11.12.1 Abeona Therapeutics Company Details
 - 11.12.2 Abeona Therapeutics Business Overview
 - 11.12.3 Abeona Therapeutics Genetic COPD Introduction
 - 11.12.4 Abeona Therapeutics Revenue in Genetic COPD Business (2018-2023)
- 11.12.5 Abeona Therapeutics Recent Developments
- 11.13 Biogen
 - 11.13.1 Biogen Company Details
 - 11.13.2 Biogen Business Overview
- 11.13.3 Biogen Genetic COPD Introduction
- 11.13.4 Biogen Revenue in Genetic COPD Business (2018-2023)
- 11.13.5 Biogen Recent Developments
- 11.14 Vertex Pharmaceuticals
 - 11.14.1 Vertex Pharmaceuticals Company Details
 - 11.14.2 Vertex Pharmaceuticals Business Overview
 - 11.14.3 Vertex Pharmaceuticals Genetic COPD Introduction
 - 11.14.4 Vertex Pharmaceuticals Revenue in Genetic COPD Business (2018-2023)
 - 11.14.5 Vertex Pharmaceuticals Recent Developments
- 11.15 Baxalta
 - 11.15.1 Baxalta Company Details
 - 11.15.2 Baxalta Business Overview
 - 11.15.3 Baxalta Genetic COPD Introduction
 - 11.15.4 Baxalta Revenue in Genetic COPD Business (2018-2023)
 - 11.15.5 Baxalta Recent Developments
- 11.16 Arrowhead Research Corporation
 - 11.16.1 Arrowhead Research Corporation Company Details
 - 11.16.2 Arrowhead Research Corporation Business Overview
 - 11.16.3 Arrowhead Research Corporation Genetic COPD Introduction
- 11.16.4 Arrowhead Research Corporation Revenue in Genetic COPD Business (2018-2023)
 - 11.16.5 Arrowhead Research Corporation Recent Developments
- 11.17 ProBioGen
- 11.17.1 ProBioGen Company Details
- 11.17.2 ProBioGen Business Overview
- 11.17.3 ProBioGen Genetic COPD Introduction
- 11.17.4 ProBioGen Revenue in Genetic COPD Business (2018-2023)
- 11.17.5 ProBioGen Recent Developments



11.18 Chiesi Pharmaceuticals

- 11.18.1 Chiesi Pharmaceuticals Company Details
- 11.18.2 Chiesi Pharmaceuticals Business Overview
- 11.18.3 Chiesi Pharmaceuticals Genetic COPD Introduction
- 11.18.4 Chiesi Pharmaceuticals Revenue in Genetic COPD Business (2018-2023)
- 11.18.5 Chiesi Pharmaceuticals Recent Developments
- 11.19 Kedrion Group
 - 11.19.1 Kedrion Group Company Details
 - 11.19.2 Kedrion Group Business Overview
 - 11.19.3 Kedrion Group Genetic COPD Introduction
 - 11.19.4 Kedrion Group Revenue in Genetic COPD Business (2018-2023)
 - 11.19.5 Kedrion Group Recent Developments
- 11.20 ProMetic Life Sciences
 - 11.20.1 ProMetic Life Sciences Company Details
 - 11.20.2 ProMetic Life Sciences Business Overview
 - 11.20.3 ProMetic Life Sciences Genetic COPD Introduction
 - 11.20.4 ProMetic Life Sciences Revenue in Genetic COPD Business (2018-2023)
 - 11.20.5 ProMetic Life Sciences Recent Developments

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details



List Of Tables

LIST OF TABLES

- Table 1. Global Genetic COPD Market Size Growth Rate by Type (US\$ Million), 2018 VS 2022 VS 2029
- Table 2. Key Players of Augmentation Therapy
- Table 3. Key Players of Cystic Fibrosis(CF)
- Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
- Table 5. Key Players of Other
- Table 6. Global Genetic COPD Market Size Growth Rate by Application (US\$ Million),
- 2018 VS 2022 VS 2029
- Table 7. Global Genetic COPD Market Size Growth Rate (CAGR) by Region (US\$
- Million): 2018 VS 2022 VS 2029
- Table 8. Global Genetic COPD Market Size by Region (2018-2023) & (US\$ Million)
- Table 9. Global Genetic COPD Market Share by Region (2018-2023)
- Table 10. Global Genetic COPD Forecasted Market Size by Region (2024-2029) & (US\$ Million)
- Table 11. Global Genetic COPD Market Share by Region (2024-2029)
- Table 12. Genetic COPD Market Trends
- Table 13. Genetic COPD Market Drivers
- Table 14. Genetic COPD Market Challenges
- Table 15. Genetic COPD Market Restraints
- Table 16. Global Genetic COPD Revenue by Players (2018-2023) & (US\$ Million)
- Table 17. Global Genetic COPD Revenue Share by Players (2018-2023)
- Table 18. Global Top Genetic COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic COPD as of 2022)
- Table 19. Global Genetic COPD Industry Ranking 2021 VS 2022 VS 2023
- Table 20. Global 5 Largest Players Market Share by Genetic COPD Revenue (CR5 and HHI) & (2018-2023)
- Table 21. Global Key Players of Genetic COPD, Headquarters and Area Served
- Table 22. Global Key Players of Genetic COPD, Product and Application
- Table 23. Global Key Players of Genetic COPD, Product and Application
- Table 24. Mergers & Acquisitions, Expansion Plans
- Table 25. Global Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 26. Global Genetic COPD Revenue Market Share by Type (2018-2023)
- Table 27. Global Genetic COPD Forecasted Market Size by Type (2024-2029) & (US\$ Million)
- Table 28. Global Genetic COPD Revenue Market Share by Type (2024-2029)



- Table 29. Global Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 30. Global Genetic COPD Revenue Share by Application (2018-2023)
- Table 31. Global Genetic COPD Forecasted Market Size by Application (2024-2029) & (US\$ Million)
- Table 32. Global Genetic COPD Revenue Share by Application (2024-2029)
- Table 33. North America Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 34. North America Genetic COPD Market Size by Type (2024-2029) & (US\$ Million)
- Table 35. North America Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 36. North America Genetic COPD Market Size by Application (2024-2029) & (US\$ Million)
- Table 37. North America Genetic COPD Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 38. North America Genetic COPD Market Size by Country (2018-2023) & (US\$ Million)
- Table 39. North America Genetic COPD Market Size by Country (2024-2029) & (US\$ Million)
- Table 40. Europe Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 41. Europe Genetic COPD Market Size by Type (2024-2029) & (US\$ Million)
- Table 42. Europe Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 43. Europe Genetic COPD Market Size by Application (2024-2029) & (US\$ Million)
- Table 44. Europe Genetic COPD Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 45. Europe Genetic COPD Market Size by Country (2018-2023) & (US\$ Million)
- Table 46. Europe Genetic COPD Market Size by Country (2024-2029) & (US\$ Million)
- Table 47. China Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 48. China Genetic COPD Market Size by Type (2024-2029) & (US\$ Million)
- Table 49. China Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 50. China Genetic COPD Market Size by Application (2024-2029) & (US\$ Million)
- Table 51. Asia Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 52. Asia Genetic COPD Market Size by Type (2024-2029) & (US\$ Million)
- Table 53. Asia Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 54. Asia Genetic COPD Market Size by Application (2024-2029) & (US\$ Million)
- Table 55. Asia Genetic COPD Growth Rate (CAGR) by Region (US\$ Million): 2018 VS 2022 VS 2029



- Table 56. Asia Genetic COPD Market Size by Region (2018-2023) & (US\$ Million)
- Table 57. Asia Genetic COPD Market Size by Region (2024-2029) & (US\$ Million)
- Table 58. Middle East, Africa, and Latin America Genetic COPD Market Size by Type (2018-2023) & (US\$ Million)
- Table 59. Middle East, Africa, and Latin America Genetic COPD Market Size by Type (2024-2029) & (US\$ Million)
- Table 60. Middle East, Africa, and Latin America Genetic COPD Market Size by Application (2018-2023) & (US\$ Million)
- Table 61. Middle East, Africa, and Latin America Genetic COPD Market Size by Application (2024-2029) & (US\$ Million)
- Table 62. Middle East, Africa, and Latin America Genetic COPD Growth Rate (CAGR) by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 63. Middle East, Africa, and Latin America Genetic COPD Market Size by Country (2018-2023) & (US\$ Million)
- Table 64. Middle East, Africa, and Latin America Genetic COPD Market Size by Country (2024-2029) & (US\$ Million)
- Table 65. Pfizer Company Details
- Table 66. Pfizer Business Overview
- Table 67. Pfizer Genetic COPD Product
- Table 68. Pfizer Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 69. Pfizer Recent Developments
- Table 70. Baxter Company Details
- Table 71. Baxter Business Overview
- Table 72. Baxter Genetic COPD Product
- Table 73. Baxter Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 74. Baxter Recent Developments
- Table 75. AstraZeneca Company Details
- Table 76. AstraZeneca Business Overview
- Table 77. AstraZeneca Genetic COPD Product
- Table 78. AstraZeneca Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 79. AstraZeneca Recent Developments
- Table 80. Grifols Company Details
- Table 81. Grifols Business Overview
- Table 82. Grifols Genetic COPD Product
- Table 83. Grifols Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 84. Grifols Recent Developments
- Table 85. Teva Pharmaceutical Industries Company Details
- Table 86. Teva Pharmaceutical Industries Business Overview



Table 87. Teva Pharmaceutical Industries Genetic COPD Product

Table 88. Teva Pharmaceutical Industries Revenue in Genetic COPD Business

(2018-2023) & (US\$ Million)

Table 89. Teva Pharmaceutical Industries Recent Developments

Table 90. Boehringer Ingelheim Company Details

Table 91. Boehringer Ingelheim Business Overview

Table 92. Boehringer Ingelheim Genetic COPD Product

Table 93. Boehringer Ingelheim Revenue in Genetic COPD Business (2018-2023) &

(US\$ Million)

Table 94. Boehringer Ingelheim Recent Developments

Table 95. Kamada Ltd Company Details

Table 96. Kamada Ltd Business Overview

Table 97. Kamada Ltd Genetic COPD Product

Table 98. Kamada Ltd Revenue in Genetic COPD Business (2018-2023) & (US\$

Million)

Table 99. Kamada Ltd Recent Developments

Table 100. GlaxoSmithKline Company Details

Table 101. GlaxoSmithKline Business Overview

Table 102. GlaxoSmithKline Genetic COPD Product

Table 103. GlaxoSmithKline Revenue in Genetic COPD Business (2018-2023) & (US\$

Million)

Table 104. GlaxoSmithKline Recent Developments

Table 105. CSL Behring Company Details

Table 106. CSL Behring Business Overview

Table 107. CSL Behring Genetic COPD Product

Table 108. CSL Behring Revenue in Genetic COPD Business (2018-2023) & (US\$

Million)

Table 109. CSL Behring Recent Developments

Table 110. Takeda Company Details

Table 111. Takeda Business Overview

Table 112. Takeda Genetic COPD Product

Table 113. Takeda Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)

Table 114. Takeda Recent Developments

Table 115. LFB Biomedicaments Company Details

Table 116. LFB Biomedicaments Business Overview

Table 117. LFB Biomedicaments Genetic COPD Product

Table 118. LFB Biomedicaments Revenue in Genetic COPD Business (2018-2023) &

(US\$ Million)

Table 119. LFB Biomedicaments Recent Developments



- Table 120. Abeona Therapeutics Company Details
- Table 121. Abeona Therapeutics Business Overview
- Table 122. Abeona Therapeutics Genetic COPD Product
- Table 123. Abeona Therapeutics Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 124. Abeona Therapeutics Recent Developments
- Table 125. Biogen Company Details
- Table 126. Biogen Business Overview
- Table 127. Biogen Genetic COPD Product
- Table 128. Biogen Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 129. Biogen Recent Developments
- Table 130. Vertex Pharmaceuticals Company Details
- Table 131. Vertex Pharmaceuticals Business Overview
- Table 132. Vertex Pharmaceuticals Genetic COPD Product
- Table 133. Vertex Pharmaceuticals Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 134. Vertex Pharmaceuticals Recent Developments
- Table 135. Baxalta Company Details
- Table 136. Baxalta Business Overview
- Table 137. Baxalta Genetic COPD Product
- Table 138. Baxalta Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 139. Baxalta Recent Developments
- Table 140. Arrowhead Research Corporation Company Details
- Table 141. Arrowhead Research Corporation Business Overview
- Table 142. Arrowhead Research Corporation Genetic COPD Product
- Table 143. Arrowhead Research Corporation Revenue in Genetic COPD Business
- (2018-2023) & (US\$ Million)
- Table 144. Arrowhead Research Corporation Recent Developments
- Table 145. ProBioGen Company Details
- Table 146. ProBioGen Business Overview
- Table 147. ProBioGen Genetic COPD Product
- Table 148. ProBioGen Revenue in Genetic COPD Business (2018-2023) & (US\$
- Million)
- Table 149. ProBioGen Recent Developments
- Table 150. Chiesi Pharmaceuticals Company Details
- Table 151. Chiesi Pharmaceuticals Business Overview
- Table 152. Chiesi Pharmaceuticals Genetic COPD Product
- Table 153. Chiesi Pharmaceuticals Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)



- Table 154. Chiesi Pharmaceuticals Recent Developments
- Table 155. Kedrion Group Company Details
- Table 156. Kedrion Group Business Overview
- Table 157. Kedrion Group Genetic COPD Product
- Table 158. Kedrion Group Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 159. Kedrion Group Recent Developments
- Table 160. ProMetic Life Sciences Company Details
- Table 161. ProMetic Life Sciences Business Overview
- Table 162. ProMetic Life Sciences Genetic COPD Product
- Table 163. ProMetic Life Sciences Revenue in Genetic COPD Business (2018-2023) & (US\$ Million)
- Table 164. ProMetic Life Sciences Recent Developments
- Table 165. Research Programs/Design for This Report
- Table 166. Key Data Information from Secondary Sources
- Table 167. Key Data Information from Primary Sources



List Of Figures

LIST OF FIGURES

- Figure 1. Global Genetic COPD Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US\$ Million)
- Figure 2. Global Genetic COPD Market Share by Type: 2022 VS 2029
- Figure 3. Augmentation Therapy Features
- Figure 4. Cystic Fibrosis(CF) Features
- Figure 5. Non-CF Bronchiectasis(NCFB) Features
- Figure 6. Other Features
- Figure 7. Global Genetic COPD Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US\$ Million)
- Figure 8. Global Genetic COPD Market Share by Application: 2022 VS 2029
- Figure 9. Hospitals Case Studies
- Figure 10. Specialty Clinics Case Studies
- Figure 11. Pharmacies Case Studies
- Figure 12. Others Case Studies
- Figure 13. Genetic COPD Report Years Considered
- Figure 14. Global Genetic COPD Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 15. Global Genetic COPD Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 16. Global Genetic COPD Market Share by Region: 2022 VS 2029
- Figure 17. Global Genetic COPD Market Share by Players in 2022
- Figure 18. Global Top Genetic COPD Players by Company Type (Tier 1, Tier 2, and
- Tier 3) & (based on the Revenue in Genetic COPD as of 2022)
- Figure 19. The Top 10 and 5 Players Market Share by Genetic COPD Revenue in 2022
- Figure 20. North America Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. North America Genetic COPD Market Share by Type (2018-2029)
- Figure 22. North America Genetic COPD Market Share by Application (2018-2029)
- Figure 23. North America Genetic COPD Market Share by Country (2018-2029)
- Figure 24. United States Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 25. Canada Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 26. Europe Genetic COPD Market Size YoY (2018-2029) & (US\$ Million)
- Figure 27. Europe Genetic COPD Market Share by Type (2018-2029)
- Figure 28. Europe Genetic COPD Market Share by Application (2018-2029)
- Figure 29. Europe Genetic COPD Market Share by Country (2018-2029)



- Figure 30. Germany Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 31. France Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 32. U.K. Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 33. Italy Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 34. Russia Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 35. Nordic Countries Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 36. China Genetic COPD Market Size YoY (2018-2029) & (US\$ Million)
- Figure 37. China Genetic COPD Market Share by Type (2018-2029)
- Figure 38. China Genetic COPD Market Share by Application (2018-2029)
- Figure 39. Asia Genetic COPD Market Size YoY (2018-2029) & (US\$ Million)
- Figure 40. Asia Genetic COPD Market Share by Type (2018-2029)
- Figure 41. Asia Genetic COPD Market Share by Application (2018-2029)
- Figure 42. Asia Genetic COPD Market Share by Region (2018-2029)
- Figure 43. Japan Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 44. South Korea Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 45. China Taiwan Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 46. Southeast Asia Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 47. India Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 48. Australia Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 49. Middle East, Africa, and Latin America Genetic COPD Market Size YoY (2018-2029) & (US\$ Million)
- Figure 50. Middle East, Africa, and Latin America Genetic COPD Market Share by Type (2018-2029)
- Figure 51. Middle East, Africa, and Latin America Genetic COPD Market Share by Application (2018-2029)
- Figure 52. Middle East, Africa, and Latin America Genetic COPD Market Share by Country (2018-2029)
- Figure 53. Brazil Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 54. Mexico Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 55. Turkey Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 56. Saudi Arabia Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 57. Israel Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)



- Figure 58. GCC Countries Genetic COPD Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 59. Pfizer Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 60. Baxter Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 61. AstraZeneca Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 62. Grifols Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 63. Teva Pharmaceutical Industries Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 64. Boehringer Ingelheim Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 65. Kamada Ltd Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 66. GlaxoSmithKline Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 67. CSL Behring Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 68. Takeda Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 69. LFB Biomedicaments Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 70. Abeona Therapeutics Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 71. Biogen Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 72. Vertex Pharmaceuticals Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 73. Baxalta Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 74. Arrowhead Research Corporation Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 75. ProBioGen Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 76. Chiesi Pharmaceuticals Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 77. Kedrion Group Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 78. ProMetic Life Sciences Revenue Growth Rate in Genetic COPD Business (2018-2023)
- Figure 79. Bottom-up and Top-down Approaches for This Report
- Figure 80. Data Triangulation
- Figure 81. Key Executives Interviewed



I would like to order

Product name: Global Genetic COPD Market Insights, Forecast to 2029

Product link: https://marketpublishers.com/r/GE895B4626FBEN.html

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE895B4626FBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms